Literature DB >> 9430521

A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years).

M P Oliveira-Neto1, A Schubach, M Mattos, S C Goncalves-Costa, C Pirmez.   

Abstract

The efficacy of an antimony regimen at the dose of 20 mg/kg/day for a 3-4-week period is well established in the treatment of American cutaneous leishmaniasis. Several drug side effects, however, have been described and the search for more suitable regimens is advisable. In the present paper, the effect of a low dose (5 mg/kg/day for 30 days) of antimony was evaluated in 159 individuals from endemic regions of Rio de Janeiro State, Brazil, an area of Leishmania (V.) braziliensis transmission. Patients presented typical cutaneous lesions and parasites were demonstrated in all cases. One hundred forty-three patients were available for evaluation and of these, 120 (84%) were cured by the end of therapy. Twenty-three patients (16%) were considered treatment failures. Side effects were observed in only six patients (4%). Extensive follow-up (up to 10 years) disclosed no relapses or mucosal lesions. The results show that a low dose of antimony is less toxic, more appropriate, especially in children and elderly people, and has the same final result as that obtained with larger doses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9430521     DOI: 10.4269/ajtmh.1997.57.651

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

1.  In Vitro Sensitivity of Cutaneous Leishmania Promastigote Isolates Circulating in French Guiana to a Set of Drugs.

Authors:  Marine Ginouvès; Stéphane Simon; Mathieu Nacher; Magalie Demar; Bernard Carme; Pierre Couppié; Ghislaine Prévot
Journal:  Am J Trop Med Hyg       Date:  2017-02-06       Impact factor: 2.345

2.  Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment.

Authors:  Luiza C Reis; Maria Edilenza F Brito; Marina A Souza; Angela C R Medeiros; Claudio J Silva; Carlos F Luna; Valéria R A Pereira
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

3.  Variable gene expression and parasite load predict treatment outcome in cutaneous leishmaniasis.

Authors:  Camila Farias Amorim; Fernanda O Novais; Ba T Nguyen; Ana M Misic; Lucas P Carvalho; Edgar M Carvalho; Daniel P Beiting; Phillip Scott
Journal:  Sci Transl Med       Date:  2019-11-20       Impact factor: 17.956

4.  Comparative efficacies of two antimony regimens to treat Leishmania braziliensis-induced cutaneous Leishmaniasis in rhesus macaques (Macaca mulatta).

Authors:  G Grimaldi; R Porrozzi; K Friedrich; A Teva; R S Marchevsky; F Vieira; N Miekeley; F J R Paumgartten
Journal:  Antimicrob Agents Chemother       Date:  2009-10-12       Impact factor: 5.191

5.  The Elderly Respond to Antimony Therapy for Cutaneous Leishmaniasis Similarly to Young Patients but Have Severe Adverse Reactions.

Authors:  Alexsandro Souza do Lago; Maurício Nascimento; Augusto M Carvalho; Neuza Lago; Juliana Silva; José Roberto Queiroz; Lucas P Carvalho; Albert Schriefer; Mary Wilson; Paulo Machado; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2018-03-22       Impact factor: 2.345

6.  Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.

Authors:  Paulo R Machado; Julia Ampuero; Luiz H Guimarães; Leonardo Villasboas; Ana T Rocha; Albert Schriefer; Rosana S Sousa; Anette Talhari; Gerson Penna; Edgar M Carvalho
Journal:  PLoS Negl Trop Dis       Date:  2010-12-21

7.  Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions.

Authors:  Cristian Valencia; Jorge Arévalo; Jean Claude Dujardin; Alejandro Llanos-Cuentas; François Chappuis; Mirko Zimic
Journal:  PLoS Negl Trop Dis       Date:  2012-06-12

8.  Intrachromosomal amplification, locus deletion and point mutation in the aquaglyceroporin AQP1 gene in antimony resistant Leishmania (Viannia) guyanensis.

Authors:  Rubens Monte-Neto; Marie-Claude N Laffitte; Philippe Leprohon; Priscila Reis; Frédéric Frézard; Marc Ouellette
Journal:  PLoS Negl Trop Dis       Date:  2015-02-13

9.  Immunologic response and memory T cells in subjects cured of tegumentary leishmaniasis.

Authors:  Augusto M Carvalho; Andréa Magalhães; Lucas P Carvalho; Olívia Bacellar; Phillip Scott; Edgar M Carvalho
Journal:  BMC Infect Dis       Date:  2013-11-09       Impact factor: 3.090

10.  Evaluation of Genetic Polymorphism of Leishmania (V.) braziliensis Isolates Obtained from the Same Patient before and after Therapeutic Failure or Reactivation of Cutaneous Lesions.

Authors:  Cibele Baptista; Armando de Oliveira Schubach; Maria de Fatima Madeira; Luciana de Freitas Campos Miranda; Andressa Guimarães de Souza Pinto; Juliana Helena da Silva Barros; Fatima Conceição-Silva; Maria Ines Fernandes Pimentel; Raquel da Silva Pacheco
Journal:  J Trop Med       Date:  2012-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.